Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 5 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Keygene N V is managing 12 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are concentrated in 5 distinct art units, suggesting a focused technical portfolio. The company is working with 11 distinct examiners, indicating that most cases are being handled by different individuals despite the concentration in art units. This environment requires a strategy that accounts for varied examiner styles within a limited number of technical groups.
MATTHEW R KEOGH is the busiest examiner, overseeing 2 pending office actions. This concentration under Keogh is the only instance of examiner overlap in the current set of 12 pending office actions. With 11 distinct examiners involved, the company faces a wide range of perspectives on its biotechnological innovations. Practitioners should focus on the 5 distinct art units to identify common trends, while remaining adaptable to the specific preferences of the 11 different examiners assigned to the portfolio.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (18%) |
| §112 only | 3 (27%) |
| Double-patenting only | 1 (9%) |
| Double-patenting + other | 1 (9%) |
| Multi-statute (no §101) | 4 (36%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHEN, YANXIN NMN | 1 | 84.6% | +26.4% |
| WILLIAMS, KEITH RICHARD | 1 | 50.0% | +0.0% |
| PAGE, BRENT T | 1 | 82.4% | +10.7% |
| STOCKDALE, JESSICA NICOLE | 1 | 51.4% | +33.3% |
| KEOGH, MATTHEW R | 1 | 78.5% | +14.4% |
| ZHONG, WAYNESHAOBIN | 1 | 72.3% | +21.4% |
| TURPIN, ZACHARY MARK | 1 | 4.0% | -5.0% |
| BAKSHI, PANCHAM | 1 | 76.7% | +30.2% |
| MEADOWS, CHRISTINA L | 1 | 74.3% | +25.2% |
| YU, TIAN NMN | 1 | 55.6% | +19.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18757549 | Delivery systems for TNE | PAGE, BRENT T | 15d |
| 19135838 | REGENERATION BY PROTOPLAST CALLUS GRAFTING | SHEN, YANXIN NMN | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17837904 | SEMI-SOLID STATE NUCLEIC ACID MANIPULATION | BAKSHI, PANCHAM | 16d overdue |
| 18743454 | DOUBLE DECAPITATION OF PLANTS | STOCKDALE, JESSICA NICOLE | 13d |
| 19106659 | HYDROGEL-CARRIERS FOR INDUCTION OF PLANT MORPHOGENESIS | WILLIAMS, KEITH RICHARD | — |
| 18038381 | Targeted enrichment using nanopore selective sequencing | TURPIN, ZACHARY MARK | — |
| 17118429 | NUCLEIC ACID AMPLIFICATION METHOD | YU, TIAN NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17837904 | SEMI-SOLID STATE NUCLEIC ACID MANIPULATION | BAKSHI, PANCHAM | 16d overdue |
| 17535297 | GENE FOR PARTHENOGENESIS | MEADOWS, CHRISTINA L | 9d overdue |
| 18743454 | DOUBLE DECAPITATION OF PLANTS | STOCKDALE, JESSICA NICOLE | 13d |
| 18757549 | Delivery systems for TNE | PAGE, BRENT T | 15d |
| 18737058 | METHOD TO INCREASE POLLEN FERTILITY | KEOGH, MATTHEW R | 28d |
| 18602867 | COMPLEX TRAITS USING TISSUE TECHNOLOGY | ZHONG, WAYNESHAOBIN | 72d |
| 19135838 | REGENERATION BY PROTOPLAST CALLUS GRAFTING | SHEN, YANXIN NMN | — |
| 17118429 | NUCLEIC ACID AMPLIFICATION METHOD | YU, TIAN NMN | — |
| Art Unit | Apps |
|---|---|
| 1663 | 7 |
| 1662 | 1 |
| 1682 | 1 |
| 1623 | 1 |
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19135838 | REGENERATION BY PROTOPLAST CALLUS GRAFTING | SHEN, YANXIN NMN | 1663 | §112 | Non-Final OA | — | Pending | Jun 05, 2025 |
| 19106659 | HYDROGEL-CARRIERS FOR INDUCTION OF PLANT MORPHOGENESIS | WILLIAMS, KEITH RICHARD | 1663 | §103§112 | Non-Final OA | — | Pending | Feb 26, 2025 |
| 18757549 | Delivery systems for TNE | PAGE, BRENT T | 1663 | DP | Final Rejection | 15d | Pending | Jun 28, 2024 |
| 18743454 | DOUBLE DECAPITATION OF PLANTS | STOCKDALE, JESSICA NICOLE | 1663 | §103§112 | Final Rejection | 13d | Pending | Jun 14, 2024 |
| 18737058 | METHOD TO INCREASE POLLEN FERTILITY | KEOGH, MATTHEW R | 1663 | §112 | Final Rejection | 28d | Pending | Jun 07, 2024 |
| 18602867 | COMPLEX TRAITS USING TISSUE TECHNOLOGY | ZHONG, WAYNESHAOBIN | 1662 | §103 | Non-Final OA | 72d | Pending | Mar 12, 2024 |
| 18038381 | Targeted enrichment using nanopore selective sequencing | TURPIN, ZACHARY MARK | 1682 | §112DP | Final Rejection | — | Pending | May 23, 2023 |
| 17837904 | SEMI-SOLID STATE NUCLEIC ACID MANIPULATION | BAKSHI, PANCHAM | 1623 | §102§103 | Non-Final OA | 16d overdue | Pending | Jun 10, 2022 |
| 17535297 | GENE FOR PARTHENOGENESIS | MEADOWS, CHRISTINA L | 1663 | §112 | Final Rejection | 9d overdue | Pending | Nov 24, 2021 |
| 17118429 | NUCLEIC ACID AMPLIFICATION METHOD | YU, TIAN NMN | 1681 | §103§112 | Non-Final OA | — | Pending | Dec 10, 2020 |
| 17081832 | GENES FOR HORMONE-FREE PLANT REGENERATION | BOGGS, RUSSELL T | 1663 | §103 | Non-Final OA | — | Pending | Oct 27, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKeygene N V has 11 pending office actions as of October 2026, spread across 5 art units and 11 examiners.
Yanxin Nmn Shen has the most, with 1 of Keygene N V's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
